Celgene Corp. (CELG +3.1%) updates guidance, saying it expects FY12 income to come in at the...

|About: Celgene Corporation (CELG)|By:, SA News Editor

Celgene Corp. (CELG +3.1%) updates guidance, saying it expects FY12 income to come in at the higher end of previous estimates and in-line results for 2013. Net product sales are expected to double between 2013 and 2017, reaching over $12B, with numerous milestones expected in 2013 for three "potential blockbuster" drugs. One of the drugs is its existing cancer drug Abraxane, which it hopes to have approved as a treatment for pancreatic cancer - which is among the hardest to treat - sometime this year.